Tezepelumab Granted Breakthrough Therapy Designation By US FDA

AZN: AstraZeneca
2018-09-07 02:00:00
Tezepelumab Granted Breakthrough Therapy Designation By US FDA For The Treatment Of Patients With Severe Asthma Without An Eosinophilic Phenotype